Shorter treatment course potentially on the horizon for hep C patients

April 15, 2016

Data from a Phase 2 clinical trial show that an investigational injectable treatment known as RG-101 in combination with a four week course of oral direct-acting antiviral (DAA) treatment was well tolerated and resulted in high virologic response rates post-treatment among Hepatitis C (HCV) infected patients with genotypes 1 and 4, who had not been treated previously.

The findings, presented today at The International Liver Congress 2016 in Barcelona, Spain are an interim analysis, with ongoing research to assess virologic response over a 48 week follow-up period to further assess the safety and efficacy of a four week course.

The investigational treatment, RG-101 works on microRNA-122, which the virus uses to replicate. Drugs that interfere with miR-122 could inhibit HCV replication, acting earlier in the viral lifecycle than currently approved HCV protease, polymerase or NS5A inhibitors.1 The current standard of care treatment in HCV consists of eight-12 weeks of DAA oral agents.2

"These early results indicate the potential for RG-101 with oral DAA combination therapy to provide an effective Hepatitis C regimen for with a short treatment course of just four weeks," said Dr Mihaly Makara from the Buda Hepatology Centre, Budapest, Hungary, and lead study author. "We very much hope the long-term, 48-week follow-up data follows the same trend."

This international study enrolled 79 patients with chronic HCV, genotype 1 or 4 who had not previously received treatment. Each patient received a 2mg/kg injection of RG-101 on Day one, with a four week course of oral DAAs (either ledipasvir/sofosbuvir, simeprevir, or daclatasvir), following by a second 2mg/kg injection of RG-101 on Day 29. The mean baseline viral load among patients was 5.805 IU/mL.

Interim analysis showed that 97.4% (37/38) and 100% (14/14) of patients at eight and 12 weeks respectiviely had a high . This was determined by assessing HCV levels 'below the lower limit of quantification' (<12 IU/mL), using the Abbot RealTimeHCV Assay, a consolidated HCV viral load and HCV genotype testing method.3

The combination therapy was generally well tolerated, with the majority of side effects reported being mild in nature, including headache and fatigue, reported in 11.4% of patients.

"It is encouraging to see a potential treatment combination on the horizon that could limit treatment duration for patients," said Professor Tom Hemming Karlsen, EASL Vice Secretary. "We will be eagerly awaiting the 48 week follow-up data."

Explore further: New triple drug combination shows promise in hepatitis C infected patients

More information: References:

1 World Hepatitis Alliance. MiR-122 inhibitor RG-101 suppresses hepatitis C virus with a single dose. Available from: www.worldhepatitisalliance.org … -c-virus-single-dose. Last accessed: March 2016.
2 EASL. EASL Recommendations on Treatment of Hepatitis C 2015. Available from: www.easl.eu/medias/cpg/HEPC-2015/Full-report.pdf. Last accessed: March 2016.
3 Abbott Molecular. Abbott RealTime HCV. Available from: www.abbottmolecular.com/products/realtime-hcv.html. Last accessed: March 2016.

Related Stories

New triple drug combination shows promise in hepatitis C infected patients

April 14, 2016
New data presented today at The International Liver Congress 2016 in Barcelona, Spain, demonstrates a high sustained virologic response (SVR) at 12 weeks from the all-oral combination of sofosbuvir/velpatasvir and experimental ...

Study demonstrates the potential for a new triple combination treatment for hepatitis C patients

April 14, 2016
A new combination treatment for hepatitis C has potential for patients who were not cured by current treatment options.

Differing perspectives on antiviral treatment efficacy in patients co-infected with HIV and HCV

April 13, 2016
Two separate studies presented today at The International Liver Congress 2016 in Barcelona, Spain have offered alternative conclusions regarding the efficacy of direct-acting antivirals (DAAs) among patients co-infected with ...

Newly approved all-oral hep C combination drug found more effective in head-to-head comparison

April 14, 2016
Findings presented today from a Phase 3 head-to-head study that compared two direct-acting antiviral treatment regimens, demonstrated that the all-oral, once daily combination of elbasvir and grazoprevir was more effective ...

More cost-effective cure for hepatitis C may be close

March 22, 2016
The cost of treating hepatitis C virus (HCV) could be cut up to 50 percent if mathematical models are used to predict when patients can safely stop taking direct-acting antiviral (DAA) medication, according to a new study ...

All-oral, DAA options for HCV effective and well tolerated in patients with decompensated cirrhosis

April 23, 2015
Interim data presented today at The International Liver Congress 2015 from the HCV-TARGET study show that all-oral, direct-acting antiviral therapy for hepatitis C (HCV) is well tolerated and highly effective in patients ...

Recommended for you

Pneumonia vaccine under development provides 'most comprehensive coverage' to date, alleviates antimicrobial concerns

October 20, 2017
In 2004, pneumonia killed more than 2 million children worldwide, according to the World Health Organization. By 2015, the number was less than 1 million.

Newly discovered viral marker could help predict flu severity in infected patients

October 20, 2017
Flu viruses contain defective genetic material that may activate the immune system in infected patients, and new research published in PLOS Pathogens suggests that lower levels of these molecules could increase flu severity.

H7N9 influenza is both lethal and transmissible in animal model for flu

October 19, 2017
In 2013, an influenza virus that had never before been detected began circulating among poultry in China. It caused several waves of human infection and in late 2016, the number of people to become sick from the H7N9 virus ...

Flu simulations suggest pandemics more likely in spring, early summer

October 19, 2017
New statistical simulations suggest that Northern Hemisphere flu pandemics are most likely to emerge in late spring or early summer at the tail end of the normal flu season, according to a new study published in PLOS Computational ...

New insights into herpes virus could inform vaccine development

October 18, 2017
A team of scientists has discovered new insights into the mechanisms of Epstein-Barr virus (EBV) infection, as well as two antibodies that block the virus' entry into cells. The findings, published in Proceedings of the National ...

Pair of discoveries illuminate new paths to flu and anthrax treatments

October 17, 2017
Two recent studies led by biologists at the University of California San Diego have set the research groundwork for new avenues to treat influenza and anthrax poisoning.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.